• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Time to change labs


With consumers investing in everything from Botox to bunion removal, it's no wonder that consumers are asking opticians, "Isn't there anything else?"

Social gatherings are filled with people talking about their latest self-improvement efforts. With today's consumer investing in everything from onabotulinumtoxinA (Botox, Allergan) to bunion removal, it's no wonder that consumers are asking opticians, "Isn't there anything else?"

Opticians, feeling the pressure to offer the latest and the greatest, may be wondering whether boutique spectacle lenses should be added to their product mix. Often, a request (or complaint) from a consumer is cited as one of the reasons given by practices that change wholesale lab services.

Although consumer preference is important and most business start-up specialists recommend that a small business-a dispensary should be run as a separate business and have its own set of financials-have accounts with at least three different labs, re-vamping spectacle products should not be just consumer-driven but confirmed through financial analysis.

The underlying questions for management to consider are:

Related Videos
 John Bladen, MBBS, BSc, MRCS, PGCert, PhD, FRCOphth, consultant ophthalmologist and oculoplastic surgeon, King's College Hospital NHS Foundation Trust, London, UK, speaks with Ophthalmology Times Europe's® Caroline Richards
rande, CFP, and John S. Grande, CFP, of Grande Financial Services, continue their discussion with Ophthalmology Times®' Sheryl Stevenson
What keeps you up at night?
S.K. Steven Houston III, MD, discusses retina innovations in use in his practice, including the NGENUITY 1.4 upgrade from Alcon
Caesar Luo, MD, shares his key take-aways on diabetic retinopathy progression in anti-VEGF versus FA implant
© 2024 MJH Life Sciences

All rights reserved.